Study: NCT06368856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin (50 mg)
Description: 50 mg de mupirocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin (50 mg)
Description: 50 mg de mupirocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin (50 mg)
Description: 50 mg de mupirocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin (500 mg)
Description: 500 mg de mupirocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin (500 mg)
Description: 500 mg de mupirocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin (500 mg)
Description: 500 mg de mupirocin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples after Single dose part
Description: 3 blood samples will be performed sampling time ater application of mupirocin (single dose part): 00h30, 1h00, 02h00

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood samples after Single dose part
Description: 3 blood samples will be performed sampling time ater application of mupirocin (single dose part): 00h30, 1h00, 02h00

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: nasal swab after Single dose part
Description: 7 nasal swab for the detection of S. aureus (type Swab) will be performed after application of mupirocin (single dose part): 00h00, 1h00, 02h00, 04h00, 06h00, 08h00, 12h00

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: nasal swab after Single dose part
Description: 7 nasal swab for the detection of S. aureus (type Swab) will be performed after application of mupirocin (single dose part): 00h00, 1h00, 02h00, 04h00, 06h00, 08h00, 12h00

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of urine after Single dose part
Description: Collection of urine during 12 hours after the application of mupirocin (Single dose part)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of urine after Single dose part
Description: Collection of urine during 12 hours after the application of mupirocin (Single dose part)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: nasal swab during Repeated dose part
Description: 5 nasal swab for the detection of S. aureus (type Swab) will be performed during administration of mupirocin (Repeated dose part): 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: nasal swab during Repeated dose part
Description: 5 nasal swab for the detection of S. aureus (type Swab) will be performed during administration of mupirocin (Repeated dose part): 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: nasal swab during Repeated dose part
Description: 5 nasal swab for the detection of S. aureus (type Swab) will be performed during administration of mupirocin (Repeated dose part): 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: nasal swab during Repeated dose part
Description: 5 nasal swab for the detection of S. aureus (type Swab) will be performed during administration of mupirocin (Repeated dose part): 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of urine during Repeated dose part
Description: 5 collections of urine during Repeated dose part: 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of urine during Repeated dose part
Description: 5 collections of urine during Repeated dose part: 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of urine during Repeated dose part
Description: 5 collections of urine during Repeated dose part: 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of urine during Repeated dose part
Description: 5 collections of urine during Repeated dose part: 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasal swab after Repeated dose part
Description: 2 nasal swab for the detection of S. aureus (type Swab) will be performed: 1, 3 months after the first application of mupirocin (Repeated dose part)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasal swab after Repeated dose part
Description: 2 nasal swab for the detection of S. aureus (type Swab) will be performed: 1, 3 months after the first application of mupirocin (Repeated dose part)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasal swab after Repeated dose part
Description: 2 nasal swab for the detection of S. aureus (type Swab) will be performed: 1, 3 months after the first application of mupirocin (Repeated dose part)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasal swab after Repeated dose part
Description: 2 nasal swab for the detection of S. aureus (type Swab) will be performed: 1, 3 months after the first application of mupirocin (Repeated dose part)